Sensei Biotherapeutics Inc (SNSE) - News Archive

: The treatment landscape for cancer, specifically resistant tumors, has taken a transformative turn with the advent of novel therapeutic agents. This article analyzes the promising results from Sensei Biotherapeutics,...

On June 13, 2025, Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage biotechnology firm focused on pioneering therapeutics for cancer treatment, announced a significant corporate action: a 1-for-20 reverse st...

Sensei Biotherapeutics Progresses with SNS-101 Clinical Development: Anticipates Full Enrollment by Q1 2025 : This article provides an examination of recent updates from Sensei Biotherapeutics regarding the clinical dev...

NEWS HEADLINE: Sensei Biotherapeutics SNS-101 Shows Promising Clinical Activity in Phase 1 Dose Escalation StudySensei Biotherapeutics, a leading biotechnology company focused on the development of immunotherapies, has...

In the rapidly evolving sphere of immuno-oncology, Sensei Biotherapeutics, Inc., a clinical-stage company, has emerged as a significant player. Raising the bar further, Sensei recently announced that the company is set...

Sensei Biotherapeutics, Inc., an immuno-oncology firm embarked on discovering and evolving next-generation therapeutics for cancer, has announced the debut of a research paper in the globally recognized Nature Communica...